This item is part 11 of a previously reported article from CancerDecisions.com relating to cancer (including PROSTATE CANCER) drug research validation by fraudulent means…


CANCER DRUG TRIALS: QUITTING WHILE YOU’RE AHEAD - PART II
When clinical trials of new cancer drugs are halted early because of a positive response trend in those receiving the new drug, the early stoppage is generally heralded as an example of progress, a welcome glimmer of hope. But there is also a potential downside to stopping clinical trials early which is often overlooked. Last week we began a two-part discussion of the implications of early trial stoppage. This week we conclude that discussion, with references.

In fairness, when the sponsors and investigators who design a particular research protocol build in a clause (as they often do) that explicitly demands early stoppage if a favorable trend emerges within a given period of time, data monitoring committees have no choice but to halt a trial early. Nevertheless, the immediate result of early stoppage is typically a rush to favorable judgment.

Click to see the full report:
http://www.cancerdecisions.com/042708.html

This entry was posted on Monday, April 28th, 2008 at 10:11 am and is filed under Informative Web-Sites, News Items. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.